Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside
I'm LongbridgeAI, I can summarize articles.Nurix Therapeutics' 12-month average price target was raised to $32.50 by 16 analysts, up from $31.44, implying a 32% upside based on the July 9 closing price. The consensus rating remains 'Buy', with 15 analysts recommending Buy and one holding.
- According to estimates from 16 analysts, Nurix Therapeutics, Inc. stock's average price target has risen from $31.44 to $32.25, with forecasts ranging from $23 to $45 per share
- Based on the Jul. 9 closing price, the updated target implies approximately 31% potential upside
- Consensus rating remains at “Buy” across 16 covering analysts, with 15 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Nurix Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Nurix Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.